MDACC Study No:2006-0977 ( NCT No: NCT00542971)
Title:Phase I-II study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006), an oral VEGF, RAF and FLT3 inhibitor, in patients with high-risk MDS and AML
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Cytarabine; Idarubicin; Sorafenib
Study Status:Terminated
Study Description:A primary goal of this clinical research study is to find the highest safe dose
of sorafenib that can be given in combination with idarubicin and Ara-C for the
treatment of acute myelogenous leukemia (AML) and high-risk, myelodysplastic
syndrome (MDS).

Once the highest safe dose is found, researchers will then try to learn if this
combination treatment can help control AML and high-risk MDS in newly diagnosed
patients. The safety of this treatment combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Cytarabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:1 to 3 times per week
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults